Literature DB >> 2579614

Klebsiella 'modifying factor': binding studies with HLA-B27+ and B27- lymphocytes.

J A Trapani, I F McKenzie.   

Abstract

On the basis that extracts of some klebsiella organisms bind selectively to the lymphocytes of HLA-B27+ individuals and induce the appearance of new antigens, attempts were made to detect the binding of klebsiella products to HLA-B27+ and B27- lymphocytes by a number of different techniques. Firstly, blocking of the binding of two different HLA-B27 specific monoclonal antibodies to HLA-B27+ lymphocytes has been examined following exposure of the lymphocytes to a cell-free culture filtrate from K. pneumoniae K21 and K43. There was no reduction in the cytotoxicity of either antibody, suggesting that neither of the epitopes detected by the anti-HLA-B27 monoclonal antibodies is a binding site for klebsiella products. Secondly, we have studied the binding of partially purified, radiolabelled klebsiella products to healthy HLA-B27+ and B27- lymphocytes. There was no significant difference either in terms of numerical counts bound or by comparing, by SDS-PAGE analysis, the molecules bound to each cell type. At the level of sensitivities of these techniques we can detect no difference in binding of klebsiella products to the lymphocytes of healthy HLA-B27+ and B27- individuals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579614      PMCID: PMC1001599          DOI: 10.1136/ard.44.3.169

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

2.  Discordance for ankylosing spondylitis in monozygotic twins.

Authors:  C J Eastmond; J C Woodrow
Journal:  Ann Rheum Dis       Date:  1977-08       Impact factor: 19.103

3.  Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis.

Authors:  K Seager; H V Bashir; A F Geczy; J Edmonds; A de Vere-Tyndall
Journal:  Nature       Date:  1979-01-04       Impact factor: 49.962

4.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

5.  Monoclonal anti-HLA-B27 antibody (B27M1): production and lack of detectable typing difference between patients with ankylosing spondylitis, Reiter's syndrome, and normal controls.

Authors:  F C Grumet; B M Fendly; E G Engleman
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

6.  The distribution of a specific HLA-B27-associated cell surface component on the tissues of patients with ankylosing spondylitis.

Authors:  K Alexander; C Edwards; I S Misko; A F Geczy; H V Bashir; J P Edmonds
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

7.  A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component.

Authors:  A F Geczy; K Alexander; H V Bashir; J Edmonds
Journal:  Nature       Date:  1980-02-21       Impact factor: 49.962

8.  Ankylosing spondylitis: klebsiella and HL-A B27.

Authors:  R Ebringer; D Cooke; D R Cawdell; P Cowling; A Ebringer
Journal:  Rheumatol Rehabil       Date:  1977-08

9.  Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease.

Authors:  R W Ebringer; D R Cawdell; P Cowling; A Ebringer
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

10.  Structural identity of human histocompatibility leukocyte antigen-B27 molecules from patients with ankylosing spondylitis and normal individuals.

Authors:  R W Karr; Y Hahn; B D Schwartz
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

View more
  1 in total

1.  Ankylosing spondylitis risk factors: a systematic literature review.

Authors:  Mark C Hwang; Lauren Ridley; John D Reveille
Journal:  Clin Rheumatol       Date:  2021-03-22       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.